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In the past decades, progestogens have been the
‘cornerstone’ of treatment for metastatic endometrial
cancer. The oestrogen receptor (ER) and progesterone
receptor (PR) levels are related to the stage, grade and
prognosis of the disease. The response to progestogens is
related to the PR-status (Table 1). However, progesto-
gens have no proven eﬀect in the adjuvant setting [1].
The optimal dose of progestogen has been debated.
In a Gynaecologic Oncology Group (GOG)-trial, ran-
domising 299 patients with metastatic endometrial can-
cer, it was shown that 200 mg of Medroxyprogesterone
Acetate (MPA) was as eﬀective as 1000 mg MPA daily
[10]. Based on this trial, a daily dose of 200 mg MPA is
recommended for the treatment of recurrent or meta-
static endometrial cancer.
Adjuvant tamoxifen treatment increases the risk of
endometrial carcinoma in breast cancer patients, with a
hazard ratio of 2.5 being reported [11]. Despite this, ta-
moxifen has also been shown to be active in advanced or
recurrent endometrial cancer, resulting in response rates
of 29% (Table 2). When tamoxifen is combined with
progestogens the response rates did not improve [20–22].
Raloxifene, another selective oestrogen receptor
modulator (SERM), is not associated with an increased
risk of endometrial cancer [23]. A newer SERM, ar-
zoxifene, has also been investigated by McMeekin and
colleague [24], and the response rate in 34 patients
treated with 20 mg was 31%. However, all these patients
were progestagen-sensitive. In a more recent European
study, 66 patients with recurrent or metastatic en-
dometrial cancer were treated with arzoxifene. In this
study, the overall response rate was 25% (34% in pro-
gestagen-sensitive patients). As with other SERMS, a
possible relationship between arzoxifene and an in-
creased risk of pulmonary embolisms was observed.
The newer third generation aromatase inhibitors have
also been explored as treatments for endometrial cancer.
In a GOG phase II study 1 mg of anastrozole was given
to 23 patients. Only 2 of 23 patients had a partial re-
mission (both were progestagen-sensitive) [25]. Other
third generation aromatase inhibitors, letrozole and
exemestane, are presently under investigation.
Danozole, interferes with the function of the pituitary
gonadotropins and is an inhibitor of ovarian
Table 1
Progesterone Receptor and response to progestagens in endometrial cancer
Authors (year) [Ref.] PR-negative PR-Positive
Responders Total Responders Total
Martin (1979) [2] 1 6 13 14
McCarthy (1979) [3] 0 8 4 5
Benraad (1980) [4] 2 7 5 6
Creasman (1980) [5] 1 8 3 5
Kauppila (1982) [6] 1 17 2 4
Pollow (1983) [7] 0 13 9 9
Quinn (1985) [8] 0 13 3 10
Ehrlich(1988) [9] 6 34 6 10
Total 11 (10%) 106 45 (71%) 63
PR, progesterone receptor.
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steroidogenesis, reversing endometrial hyperplasia in
97% of patients [26]. However, this drug produced no
responses in a GOG phase II study in recurrent en-
dometrial cancer patients (N=22) [27]. Disappointing
results were also obtained using Gonadotrophin-releas-
ing hormone (GnRH)-agonists [28].
Fulvestrant is a new type of ER antagonist that
downregulates cellular levels of the ER. Fulvestrant in-
hibits oestrogen-stimulated thickening of the en-
dometrium [29]. This compound merits further
investigation in the treatment of metastatic endometrial
cancer.
References
1. Vergote I, Kjorstad K, Abeler V, Kolstad P. Randomized trial of
adjuvant progesterone in early endometrial cancer. Cancer 1989,
64, 1011–1016.
2. Martin PM, Rolland PH, Gammerre M, Serment H., Toga M.
Estradiol and progesterone receptors in normal and neoplastic
endometrium: correlation between receptor, histopathological
examinations and clinical response under progestin therapy. Int
J Cancer 1979, 23, 321–329.
3. McCarthy KS Jr., Barton TK, Fetter BF, Creasman WT,
McCarthy KS Sr. Correlation of oestrogen and progesterone
receptors with histological diﬀerentiation in endometrial carcino-
ma. Am J Pathol 1979, 96, 171–182.
4. Benraad TJ, Friberg LG, Koenders AJM, Kullander S. Do
oestrogen and progesterone receptors (E2R and PR) in metasta-
sizing endometrial cancers predict the response to progestagen
therapy. Acta Obstet Gynecol Scand 1980, 59, 155–159.
5. CreasmanWT, McCarthy KS Sr, Barton TK, McCarthy KS Jr.
Clinical correlates of oestrogen- and progesterone-binding pro-
teins in human endometrial carcinoma. Obstet Gynecol 1980, 55,
363–370.
6. Kauppila A, Isotalo H, Kujansuu E, Vihko R. Clinical
signiﬁcance of female steroid hormone receptors in endometrial
carcinoma treated with conventional methods and medroxypro-
gesterone acetate. In: Carelli F, et al. editors. International
symposium on medroxyprogesterone acetate. Excerpta medica
international congress series No. 611. Amsterdam: Excerpta
Medica; 1982, p. 350–359.
7. Pollow K, Manz B, Grill JH. Estrorgen and progesterone
receptors in endometrial cancer. In: Jasonni VM, editor.
Steroids and endometrial cancer. New York: Raven Press;
1983, p. 33–60.
8. Quinn MA, Cauchi M, Fortune D. Endometrial carcinoma:
steroid receptors and response to medroxyprogesterone acetate.
Gynecol Oncol 1985, 21, 314–319.
9. Ehrlich CE, Young PC, Stehman FB, Sutton GP, Alford WM.
Steroid receptors and clinical outcome in patients with
adenocarcinoma of the endometrium. Am J Obstet Gynecol
1988, 158, 796–807.
10. Thipgen JT, Brady MF, Alvarez RD, Adelson MD, Homesley
HD, Manetta A, et al. Oral Medroxyprogesterone Acetate in the
treatment of advanced or recurrent endometrial carcinoma: a
dose-response study by the Gynecologic Oncology Group. J Clin
Oncol 1999, 17, 1736–1744.
11. Vergote I, Neven P, Vanderrick G, Van Dam P, Van Belle Y, De
Sutter Ph, et al. Tamoxifen and the Uterus. Eur J Cancer 1998,
34(Suppl 4), S1–S3.
12. Swenerton KD, Shaw D, White GW, Boyes DA. Treatment of
advanced endometrial carcinoma with tamoxifen. New Engl J Med
1979, 301, 105.
13. Bonte J, Ide P, Billiet G, Wynants P. Tamoxifen as a possible
chemotherapeutic agent in endometrial adenocarcinoma. Gynecol
Oncol 1981, 11, 140–161.
14. Kauppila A, Vihko R. Endometrial carcinoma insensitive to
progestin and cytotoxic chemotherapy may respond to tamoxifen.
Acta Obstet Gynecol Scand 1981, 60, 589–590.
15. Hald I, Salimtschik M, Mouridsen HT. Tamoxifen treatment of
advanced endometrial carcinoma: a phase II study. Eur J Gynecol
Oncol 1983, 4, 83–87.
16. Rendina GM, Donadio C, Fabri M, Mazzonni P, Nazzicone P.
Tamoxifen and medroxyprogesterone therapy for advanced
endometrial carcinoma. Eur J Obstet Reprod Biol 1984, 17,
285–291.
17. Slavik M, Petty WM, Blessing JA, Creasman WT, Homesley
HD. Phase II clinical study of tamoxifen in advanced
endometrial adenocarcinoma: a Gynecologic Oncology Group
study. Cancer Treat Rep 1984, 68, 809–811.
18. Edmonson JH, Krook JE, Hilton JF, et al. Ineﬀectiveness of
tamoxifen in advanced endometrial carcinoma after failure of
progestin treatment. Cancer Treat Rep 1986, 70, 1019–1020.
19. Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/
recurrent endometrial carcinoma. Gynecol Oncol 1989, 32, 1–3.
20. Carlson JA, Allerga JC, Day TG Jr, Wittliﬀ JL. Tamoxifen and
endometrial carcinoma: alterations in oestrogen and progesterone
Table 2
Tamoxifen in advanced or recurrent endometrial cancer
Author (year) [Ref.] Previous progestagen Responders Total
Swenerton (1979) [12] Yes 4 7
Bonte (1981) [13] Yes 10 17
Kauppila (1981) [14] Yes 1 1
Hald (1983) [15] Yes 2 9
No 6 17
Rendina (1984) [16] No 24 45
Slavik (1984) [17] Yes 0 24
Edmonson (1986) [18] Yes 0 22
No 5 24
Quinn (1989) [19] Yes 10 49
Total Yes or no 62 (29%) 215
Yes 27 (21%) 129
No 35 (41%) 86
68 I. Vergote et al. / EJC Supplements Vol 2 No. 9 (2004) 67–69
receptors in untreated patients and combination hormonal therapy
in advanced neoplasia. Am J Obstet Gynecol 1984, 149, 149–153.
21. Kline R, Freedman RS, Jones LA, Atkinson EN. Treatment of
recurrent or metastatic poorly diﬀerentiated adenocarcinoma of
the endometrium with tamoxifen and medroxyprogesterone
acetate. Cancer Treat Rep 1987, 71, 327–328.
22. Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK,
Schinella RA, et al. Megestrol and tamoxifen in patients with
advanced endometrial cancer. Am J Clin Oncol 2001, 24, 43–
46.
23. Cauley JA, Norton L, LippmanME, Eckert S, Krueger KA, Purdie
DW, et al. Continued breast cancer risk reduction in postmenopau-
sal women treated with raloxifene: 4 year results from the MORE
trial.Multiple outcomes of raloxifene evaluation.Breast CancerRes
Treat 2001, 65, 125–134.
24. McMeekin DS, Gordon A, Fowler J, Melemed A, Buller R, Burke
T, et al. A phase II trial of arzoxifene, a selective oestrogen
response modulator in patients with recurrent or advanced
endometrial cancer. Gynecol Oncol 2003, 90, 64–69.
25. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A
phase II trial of Anastrozole in advanced recurrent or persistent
endometrial carcinoma: a Gynaecologic Oncology Group Study.
Gynecol Oncol 2000, 78, 212–216.
26. Soh E, Sato K. Clinical eﬀects of danazol on endometrial
hyperplasia in menopausal and postmenopausal women. Cancer
1990, 66, 983–988.
27. Covens A, Brunetto VL, Markman M, Orr JW, Lentz SS, Benda J.
Phase II trial of danazol in advanced, recurrent, or persistent
endometrial cancer: a Gynecologic Oncology Group Study.
Gynecol Oncol 2003, 89, 470–474.
28. Elit L, Hirte H. Current status and future innovations of
hormonal agents, chemotherapy and investigational agents in
endometrial cancer. Curr Opin Obstet Gynecol 2002, 14,
67–73.
29. Addo S, Yates RA, Laight A. A phase I trial to assess the
pharmacology of the new oestrogen receptor antagonist fulves-
trant on the endometrium in healthy postmenopausal volunteers.
Br J Cancer 2002, 87, 1354–1359.
I. Vergote et al. / EJC Supplements Vol 2 No. 9 (2004) 67–69 69
